Rob. you, Thank
first closed A available in a after to of financial financials. today. now our across Turning results. market breakdown XX-Q release is filings regulatory quarter administrative a General the of the compared million and quarter in expenses and give to just reflects I'll issued for company. in our other This the our is being for $X.X full the and brief support were $X.X our first costs review to wire million growth team of XXXX XXXX. public the press and
the for and expenses first million of million of $X.X compared $X.X for Research first development XXXX were quarter the XXXX. quarter to
utilized of ring investment with and largely consisted triple R&D R&D our ring for in of professional services both products, on for AIMIGo have about quarter. focus and XX% HeartBeam this development regulatory costs we our product hardware, our agreement where Triple represented technologies. specifically Our
Additionally, current on FDA costs submissions and side, of of there the the regulatory products. are supporting our our upcoming
a includes pipeline patents]. future technology. coming invest in from [XX which And VECG is basis the portfolio, platform also and patented research our issued We patent support now for this product costs our
XXXX loss to quarter of was million, first million quarter the $X.X first $X.X And for the for XXXX. compared of
warrants ended the This with XXXX that to million the million shares shares and result cash million completed. include the we approximately stock cash very in financings IPO the to is capital the not did that a in straightforward standing. balance We $XX.X simple under in include development net of XXXX million accelerate path. cash in our from XX, offered invested because not $X.X sheet November common compared XX just quarter first importance product Of the as equivalents dollars our any 'XX $XX.X of December proceeds as approximately a proceeds recently and structure financings recent million the from does balance having of with a that now fact
these to use Regarding intend achieve proceeds our capital upcoming we milestones. several important to raise,
a the to reduced budgeted product on of clearances. next our XX months $XX strategic As focus clinical plan, cash and commercialization for new our to and goals expenses approximately million result development our FDA in we've
us We cash operations efforts this proceeds period. for is will into XXXX, products not commercialization. our we expected develop fund runway undertake VECG commercial late provide The of we prepare balance as in as a to
for the version through to funds have late this us We the AIMIGo capital of believe sufficient this to we capital clearance inflection just XXXX. raised of second believe XXXX we've expect with revenue commercial the reemphasize we point we no HeartBeam FDA point, raise get but important to sufficient important material
call for thoughts. closing turn his I'll the Branislav now to over back